491 related articles for article (PubMed ID: 27526684)
21. Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphoma.
Gebauer N; Hardel TT; Gebauer J; Bernard V; Merz H; Feller AC; Rades D; Biersack H; Lehnert H; Thorns C
Anticancer Res; 2014 Oct; 34(10):5503-7. PubMed ID: 25275047
[TBL] [Abstract][Full Text] [Related]
22. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
[No Abstract] [Full Text] [Related]
23. An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.
Flümann R; Rehkämper T; Nieper P; Pfeiffer P; Holzem A; Klein S; Bhatia S; Kochanek M; Kisis I; Pelzer BW; Ahlert H; Hauer J; da Palma Guerreiro A; Ryan JA; Reimann M; Riabinska A; Wiederstein J; Krüger M; Deckert M; Altmüller J; Klatt AR; Frenzel LP; Pasqualucci L; Béguelin W; Melnick AM; Sander S; Montesinos-Rongen M; Brunn A; Lohneis P; Büttner R; Kashkar H; Borkhardt A; Letai A; Persigehl T; Peifer M; Schmitt CA; Reinhardt HC; Knittel G
Blood Cancer Discov; 2021 Jan; 2(1):70-91. PubMed ID: 33447829
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.
Hallas C; Preukschas M; Tiemann M
Leuk Res; 2019 Jan; 76():107-111. PubMed ID: 30360939
[TBL] [Abstract][Full Text] [Related]
25. NF-kappaB down-regulates expression of the B-lymphoma marker CD10 through a miR-155/PU.1 pathway.
Thompson RC; Herscovitch M; Zhao I; Ford TJ; Gilmore TD
J Biol Chem; 2011 Jan; 286(3):1675-82. PubMed ID: 20947507
[TBL] [Abstract][Full Text] [Related]
26. Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderly.
Gebauer N; Gebauer J; Hardel TT; Bernard V; Biersack H; Lehnert H; Rades D; Feller AC; Thorns C
Leuk Lymphoma; 2015 Apr; 56(4):1100-6. PubMed ID: 25030036
[TBL] [Abstract][Full Text] [Related]
27. Gain-of-function mutations in CARD11 promote enhanced aggregation and idiosyncratic signalosome assembly.
Stinson JR; Dorjbal B; McDaniel DP; David L; Wu H; Snow AL
Cell Immunol; 2020 Jul; 353():104129. PubMed ID: 32473470
[TBL] [Abstract][Full Text] [Related]
28. Synergistic activity of Card11 mutant and Bcl6 in the development of diffuse large B-cell lymphoma in a mouse model.
Takahara T; Matsuo K; Seto M; Nakamura S; Tsuzuki S
Cancer Sci; 2016 Nov; 107(11):1572-1580. PubMed ID: 27560392
[TBL] [Abstract][Full Text] [Related]
29. The biological and clinical impact of inhibition of NF-κB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL).
Bavi P; Uddin S; Bu R; Ahmed M; Abubaker J; Balde V; Qadri Z; Ajarim D; Al-Dayel F; Hussain AR; Al-Kuraya KS
J Pathol; 2011 Jul; 224(3):355-66. PubMed ID: 21506127
[TBL] [Abstract][Full Text] [Related]
30. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.
Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G
Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863
[TBL] [Abstract][Full Text] [Related]
31. VR09 cell line: an EBV-positive lymphoblastoid cell line with in vivo characteristics of diffuse large B cell lymphoma of activated B-cell type.
Nichele I; Zamò A; Bertolaso A; Bifari F; Tinelli M; Franchini M; Stradoni R; Aprili F; Pizzolo G; Krampera M
PLoS One; 2012; 7(12):e52811. PubMed ID: 23285191
[TBL] [Abstract][Full Text] [Related]
32. Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen.
Lam LT; Davis RE; Ngo VN; Lenz G; Wright G; Xu W; Zhao H; Yu X; Dang L; Staudt LM
Proc Natl Acad Sci U S A; 2008 Dec; 105(52):20798-803. PubMed ID: 19104039
[TBL] [Abstract][Full Text] [Related]
33. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
34. Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R; Hansen J; Pelzer BW; Nieper P; Lohmann T; Kisis I; Riet T; Kohlhas V; Nguyen PH; Peifer M; Abedpour N; Bosco G; Thomas RK; Kochanek M; Knüfer J; Jonigkeit L; Beleggia F; Holzem A; Büttner R; Lohneis P; Meinel J; Ortmann M; Persigehl T; Hallek M; Calado DP; Chmielewski M; Klein S; Göthert JR; Chapuy B; Zevnik B; Wunderlich FT; von Tresckow B; Jachimowicz RD; Melnick AM; Reinhardt HC; Knittel G
Blood Cancer Discov; 2023 Jan; 4(1):78-97. PubMed ID: 36346827
[TBL] [Abstract][Full Text] [Related]
35. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma.
Milhollen MA; Traore T; Adams-Duffy J; Thomas MP; Berger AJ; Dang L; Dick LR; Garnsey JJ; Koenig E; Langston SP; Manfredi M; Narayanan U; Rolfe M; Staudt LM; Soucy TA; Yu J; Zhang J; Bolen JB; Smith PG
Blood; 2010 Sep; 116(9):1515-23. PubMed ID: 20525923
[TBL] [Abstract][Full Text] [Related]
36. Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?
Di Rocco A; De Angelis F; Ansuinelli M; Foà R; Martelli M
Expert Rev Hematol; 2017 Sep; 10(9):761-774. PubMed ID: 28712322
[TBL] [Abstract][Full Text] [Related]
37. The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.
Twa DDW; Mottok A; Savage KJ; Steidl C
Blood Rev; 2018 May; 32(3):249-255. PubMed ID: 29289361
[TBL] [Abstract][Full Text] [Related]
38. A20, ABIN-1/2, and CARD11 mutations and their prognostic value in gastrointestinal diffuse large B-cell lymphoma.
Dong G; Chanudet E; Zeng N; Appert A; Chen YW; Au WY; Hamoudi RA; Watkins AJ; Ye H; Liu H; Gao Z; Chuang SS; Srivastava G; Du MQ
Clin Cancer Res; 2011 Mar; 17(6):1440-51. PubMed ID: 21266526
[TBL] [Abstract][Full Text] [Related]
39. A multiprotein supercomplex controlling oncogenic signalling in lymphoma.
Phelan JD; Young RM; Webster DE; Roulland S; Wright GW; Kasbekar M; Shaffer AL; Ceribelli M; Wang JQ; Schmitz R; Nakagawa M; Bachy E; Huang DW; Ji Y; Chen L; Yang Y; Zhao H; Yu X; Xu W; Palisoc MM; Valadez RR; Davies-Hill T; Wilson WH; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Delabie J; Rimsza LM; Rodriguez FJ; Estephan F; Holdhoff M; Kruhlak MJ; Hewitt SM; Thomas CJ; Pittaluga S; Oellerich T; Staudt LM
Nature; 2018 Aug; 560(7718):387-391. PubMed ID: 29925955
[TBL] [Abstract][Full Text] [Related]
40. miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis.
Kozloski GA; Jiang X; Bhatt S; Ruiz J; Vega F; Shaknovich R; Melnick A; Lossos IS
Blood; 2016 Jun; 127(23):2856-66. PubMed ID: 26941399
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
